#199 - Aubrey de Grey - The Man Who Says Ageing Can Be Cured

— Aging is accumulated damage in a biological machine, not an inevitable mystery—the body's self-repair systems are imperfect but can be engineered to repair damage faster than it accumulates.

— Seven categories of damage drive aging: stem cell depletion, mitochondrial dysfunction, cellular senescence, extracellular matrix stiffness, waste product accumulation, telomere shortening, and epigenetic changes.

— De Grey assigns a 50/50 chance of reaching "longevity escape velocity" (practical defeat of aging) within 12–15 years, though timeframes slip; most experts avoid such predictions due to fear of losing funding credibility.

— Rejuvenation will likely involve multiple gene therapies and cell therapies delivered as injections rather than pills; early treatments may include surgery, but injectable approaches will dominate.

— Population, fertility, social care, and meaning will adapt as aging is solved; death remains distinct from aging and cannot be eliminated by medicine, though accidents and aging-related disease can be nearly eliminated.

— Funding is the critical bottleneck: early-stage mouse research (the hardest to fund) requires only $5–10 million per large experiment, yet most billionaires decline to invest, citing religious concerns, pessimism about timelines, or competing bets on AI.

— De Grey's 12–15 year timeframe for longevity escape velocity in mice is a key inflection point; if a cocktail of damage-repair treatments doubles the lifespan gains of calorie restriction in aged mice, expert consensus will shift dramatically and unlock public and private capital.

— A "Robust Mouse Rejuvenation" study is underway at de Grey's LEV Foundation; tracking breakthroughs in stem cell therapy, gene therapy for lipofuscin removal, and extracellular matrix bond-breaking could signal acceleration toward human trials and justify long-term conviction in the longevity field.

— Longevity treatments will be free or subsidized globally, not luxury goods, because the economic return on keeping people productive and healthy will dwarf treatment costs; early-stage researchers and foundations remain severely underfunded relative to the problem's scale (110,000 deaths per day from aging).